Delivery Order SPE2DB22D1202-SPE2DB25FVMD6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,808.18 to AmerisourceBergen Drug Corp for Synvisc-One Syringes (6mL), a hyaluronic acid-based injectable treatment for osteoarthritis. This firm fixed-price, competitively awarded delivery order was issued on September 18, 2025, with an ultimate completion date of September 19, 2025, and will be performed at the awardee's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency valued at $10,419.84 for Synvisc-One Syringe 6ML, a hyaluronic acid-based joint injection used to treat osteoarthritis pain. The contract, awarded on June 2, 2025, with an ultimate completion date of June 3, 2025, is a firm fixed price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This award represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Synvisc-One Syringe 6mL, a hyaluronic acid-based joint injection used for osteoarthritis treatment. This competitively awarded, non-set-aside contract was finalized on August 18, 2025, with a ceiling value of $4,087.80 and a firm fixed price structure. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. This...
- The Defense Logistics Agency awarded a $25.2K delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid-based joint injection used for osteoarthritis treatment. This firm fixed-price, non-set-aside contract is scheduled for completion by September 18, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement under the company's existing...
- The Defense Logistics Agency awarded a $8,624.13 delivery order to AmerisourceBergen Drug Corp for Synvisc-One Syringe 6ML, a hyaluronic acid-based intra-articular injection used for osteoarthritis pain management. Issued on September 2, 2025, with completion targeted for September 3, 2025, this firm fixed price delivery order was competitively awarded without set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used for knee osteoarthritis treatment. This non-set-aside, competitively awarded contract carries a ceiling value of $11,322.76 under a firm fixed price arrangement, with an ultimate completion date of August 22, 2025. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 6, 2025, for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used for osteoarthritis treatment. This firm fixed price delivery order, valued at $5,019.40, represents a competitive award with no set-aside designation and is scheduled for completion by August 7, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used in orthopedic and rheumatological applications. The contract, valued at $14,689.32, is a firm fixed price delivery order with an ultimate completion date of August 1, 2025. This award represents a non-set-aside, competitively awarded contract supporting the federal medical procurement needs of military and veteran healthcare systems....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used for osteoarthritis treatment. Valued at $7,796.10 with a firm fixed price structure, this non-set-aside delivery order is scheduled for completion by August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a child delivery order under...
- The Defense Logistics Agency awarded a delivery order valued at $1,605.68 to AmerisourceBergen Drug Corp for SYNVISC-One Syringe 6ml, a hyaluronic acid-based joint injection used to treat osteoarthritis symptoms. The contract, issued on September 9, 2025, with a completion date of September 10, 2025, represents a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, a major pharmaceutical distributor headquartered in...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVMD6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,484.68 to AmerisourceBergen Drug Corp for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid-based injectable treatment for osteoarthritis. The contract, issued on September 23, 2025, with an ultimate completion date of September 24, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. Performance will be executed from AmerisourceBergen's Conshohocken, Pennsylvania facility, the company's corporate headquarters and primary distribution hub. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 prime vendor contract running through December 2026 that serves as the primary global pharmaceutical support vehicle for military healthcare systems. The underlying IDC enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical commodities to support Defense Health Agency operations and other federal healthcare systems worldwide. The company's extensive federal contract portfolio demonstrates its established capability to meet military medical procurement requirements through competitive processes across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 9/23/25 |